The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.
Barbara RuaroMarco ConfalonieriFrancesco SaltonBarbara WadeElisa BaratellaPietro GeriPaola ConfalonieriMetka KodricMarco BioloCosimo BruniPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Systemic sclerosis (SSc) is an autoimmune disease, characterized by the presence of generalized vasculopathy and tissue fibrosis. Collagen vascular disorder in SSc is due to fibroblast and endothelial cell dysfunctions. This leads to collagen overproduction, vascular impairment and immune system abnormalities and, in the last stage, multi-organ damage. Thus, to avoid organ damage, which has a poor prognosis, all patients should be carefully evaluated and followed. This is particularly important in the initial disease phase, so as to facilitate early identification of any organ involvement and to allow for appropriate therapy. Pulmonary disease in SSc mainly involves interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH). High-resolution computed tomography (HRCT) and pulmonary function tests (PFT) have been proposed to monitor parenchymal damage. Although transthoracic echocardiography is the most commonly used screening tool for PAH in SSc patients, definitive diagnosis necessitates confirmation by right heart catheterization (RHC). Moreover, some studies have demonstrated that nailfold videocapillaroscopy (NVC) provides an accurate evaluation of the microvascular damage in SSc and is able to predict internal organ involvement, such as lung impairment. This review provides an overview of the correlation between lung damage and microvascular involvement in SSc patients.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- end stage renal disease
- pulmonary arterial hypertension
- pulmonary hypertension
- chronic kidney disease
- ejection fraction
- computed tomography
- poor prognosis
- oxidative stress
- pulmonary artery
- rheumatoid arthritis
- heart failure
- left ventricular
- stem cells
- squamous cell carcinoma
- radiation therapy
- positron emission tomography
- multiple sclerosis
- idiopathic pulmonary fibrosis
- mesenchymal stem cells
- replacement therapy